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Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by g-secretase inhibitors has been shown to
be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine.
Methods: A multi-centre, non-randomised Bayesian adaptive design study of MK-0752, administered per os weekly, in
combination with gemcitabine administered intravenously on days 1, 8 and 15 (28 day cycle) at 800 or 1000mgm-2, was performed
to determine the safety of combination treatment and the recommended phase 2 dose (RP2D). Secondary and tertiary objectives
included tumour response, plasma and tumour MK-0752 concentration, and inhibition of the Notch pathway in hair follicles and
tumour.
Results: Overall, 44 eligible patients (performance status 0 or 1 with adequate organ function) received gemcitabine and MK-0752
as first or second line treatment for pancreatic cancer. RP2Ds of MK-0752 and gemcitabine as single agents could be combined
safely. The Bayesian algorithm allowed further dose escalation, but pharmacokinetic analysis showed no increase in MK-0752 AUC
(area under the curve) beyond 1800mg once weekly. Tumour response evaluation was available in 19 patients; 13 achieved stable
disease and 1 patient achieved a confirmed partial response.
Conclusions: Gemcitabine and a g-secretase inhibitor (MK-0752) can be combined at their full, single-agent RP2Ds.
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Pancreatic cancer is one of the most lethal human cancers because
of late presentation, early metastases and resistance of tumour cells
to most conventional treatments. Until recently, the standard
treatment in the metastatic setting remained gemcitabine. Other
approaches now considered include the FOLFIRINOX regime and
the combination of gemcitabine and abraxane (Conroy et al, 2011;
Von Hoff et al, 2013). As the majority of patients with pancreatic
cancer develop advanced metastatic disease, and chemotherapeu-
tics have limited impact on survival, improvements in systemic-
targeted therapies are desperately needed.
Studies of the molecular genetics of human pancreatic ductal
adenocarcinoma (PDAC) have identified a number of common
genetic alterations (Jones et al, 2008); however, targeted therapies
have not been shown to be beneficial. In addition, advances have
been made in the understanding of pancreatic developmental
biology and the identification of developmental signalling path-
ways that are important in PDAC, including the Notch pathway
(Miyamoto et al, 2003; Cook et al, 2012). The Notch pathway is
involved in the development, differentiation, growth and fate of
multiple different cell types (Bray, 2006), and has a fairly limited
set of known target genes, including transcriptional regulators Hes
(hairy/enhancer of split) and Hey (subfamily of Hes) (Borggrefe
and Oswald, 2009). Notch signalling is relatively inactive in the
normal adult pancreas; however, it becomes activated in damaged
and dysplastic pancreatic tissue (Miyamoto et al, 2003). In humans,
PDAC activation of the Notch pathway has been shown to
correlate with neurovascular metastasis (Buchler et al, 2005), and
over-expression of Notch3 has been linked to a more aggressive
phenotype and resistance to chemotherapy (Doucas et al, 2008;
Yao and Qian, 2009). This perhaps indicates that Notch not only
has a role in development of PDAC, but also in its maintenance
and progression.
Most Notch ligands and receptors are upregulated in PDAC
therefore pan-Notch inhibition is likely to be more useful than
inhibiting a single component of the pathway. Pan-Notch
inhibition is possible pharmacologically with g-secretase inhibitors
(GSIs). g-secretase is the crucial proteolytic activity that releases
the Notch intracellular domain and is therefore a key player in the
canonical Notch signalling pathway. GSIs prevent cleavage of the
intracellular Notch domains by blocking the proteolytic function of
presenilin enzymes, thereby keeping Notch in an intact, latent
form. GSIs have been shown to be effective in genetically
engineered mouse models of PDAC, alone and in combination
with gemcitabine (Plentz et al, 2009; Cook et al, 2012).
MK-0752 is a highly potent and specific GSI (Krop et al, 2012).
MK-0752 appears to be well tolerated as a single-agent and
toxicities appear to be schedule dependent (Krop et al, 2012). A
preference for a once weekly dosing schedule is dictated by
tolerability, pharmacodynamic (PD) activity and pharmacokinetic
(PK) results (Krop et al, 2012). Observed PK and PD data from
phase I studies of MK-0752 alone suggested no significant increase
in drug exposure between 1800mg and 3200mg, and the
maximum tolerated dose (MTD) on the weekly schedule was
defined as 3200mg. The recommended dose for further phase II
evaluation (RP2D) of MK-0752 in single-agent studies is 1800mg;
however, the combination of MK-0752 and gemcitabine has not
previously been reported. Gemcitabine (20,20,-difluoro-20,-deoxy-
cytidine) is a nucleoside analogue of deoxycytidine that interferes
with DNA synthesis through inhibition of ribonucleotide reductase
and competition with dCTP for incorporation into DNA. It has
broad applications as a cytotoxic chemotherapeutic agent in
multiple solid tumour types, and is used as a standard treatment in
pancreatic cancer (Burris et al, 1997).
The primary objective of this trial was to recommend a dose for
further phase II evaluation for the combination of MK-0752 and
gemcitabine; and determine the safety and tolerability of
combination treatment. Secondary objectives included evaluation
of tumour response, measuring time to disease progression, overall
survival at 6 months and 1 year, and percentage change in CA19-9
levels. Tertiary objectives included investigations into the PK
profile of MK-0752 in plasma, the feasibility of measuring MK-
0752 levels in tumour and assessment of PD markers of target
inhibition by MK-0752.
PATIENTS AND METHODS
Patient eligibility. Patients with histologically or cytologically
proven stage III (inoperable) and IV PDAC were eligible for the
trial. Previous chemotherapy for advanced disease was permitted.
If gemcitabine treatment had been given previously, the patient
must have tolerated a dose of at least 800mgm-2. Patients were
required to have radiologically assessable disease and tissue that
was accessible to biopsy. Other inclusion criteria included a life
expectancy of at least 12weeks, World Health Organisation
(WHO) performance status of 0 or 1 and the following
haematological and biochemical parameters; haemoglobin X9 g
dl-1; absolute neutrophil count X1.5 109 l-1; platelet count
X100 109 l-1; serum bilirubin p1.5 upper limit of normal
(ULN); alanine amino-transferase (ALT) p2.5ULN (unless
raised due to liver metastases in which case up to 5ULN was
permissible); prothrombin time (PT) p1.5ULN and calculated
creatinine clearance X50mlmin-1. All patients gave written
informed consent in accordance with the institutional guidelines
before study treatment.
Study design. This was a multi-centre, non-randomised Bayesian
adaptive phase I study of MK-0752, administered per os (p.o.)
weekly in combination with gemcitabine administered intrave-
nously (IV) on days 1, 8 and 15 (800 or 1000mgm-2) with MK-
0752 administered alone on day 22 (28 day cycle) (https://
clinicaltrials.gov/ct2/show/NCT01098344). Cycle 1 had a duration
of 42 days (treatment with MK-0752 alone administered on day -
14 and day -7); subsequent cycles were 28 days in duration. The
study was conducted in accordance with the Declaration of
Helsinki and the International Conference on Harmonization
Good Clinical Practice Guidelines and approved by relevant
regulatory and independent ethics committee (NRES Committee
East of England—Cambridge East Ref: 10/H0304/3). Six UK sites
participated.
The Bayesian bivariate dose escalation procedure was conducted
through the direction of a computer programme operated by the
Medical and Pharmaceutical (MPS) Research Unit at Lancaster
University (Whitehead et al, 2012). The starting dose of the phase I
dose escalation stage of the study was based on the results of
previous and ongoing phase I trials of MK-0752 in patients with
solid tumours. The decision to dose escalate and the number of
patients to be treated at any given dose level (beyond one patient)
was made by the Investigators after review of all available toxicity
data and output from the Bayesian algorithm (Supplementary
Figure 1).
The DLT and MTD were defined using the National Cancer
Institute (NCI) Common Terminology Criteria for Adverse Events
(CTCAE) Version 4.02. The MTD was defined as the dose most
likely to be associated with a risk of a DLT, during the first cycle of
a patient’s treatment, of 20%. A DLT was defined as almost
certainly or probably drug-related and occurring in the first cycle
of treatment, including grade 4 neutropenia forX5 days duration;
febrile neutropenia; grade 4 thrombocytopenia for X5 days; grade
3 or 4 toxicity to organs other than the bone marrow, including
grade 3 and 4 biochemical adverse events (AEs) as DLTs but
excluding grade 3 nausea, vomiting or diarrhoea in patients who
have not received optimal treatment. The phase I dose escalation
part of the study was considered to be complete either when the
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same treatment combination had been recommended and
administered nine times (to different patients), or when the safety
and clinical profile indicate that the RP2D of MK-0752 in single-
agent studies given in combination with either 800mgm-2 or
1000mgm-2 gemcitabine should become the recommended dose
combination for phase 2.
Patient evaluation. All patients receiving at least one administra-
tion of MK-0752 were evaluable for toxicity. Patients who did not
complete the first cycle of treatment for reasons other than DLTs
were not evaluable for the determination of the MTD and were
replaced. All patients who met eligibility criteria, received at least
one cycle of treatment with MK-0752 alone followed by MK-0752
in combination with gemcitabine, were assessed for efficacy. To be
evaluable for response, patients were to have received at least two
cycles of study medication, had a baseline assessment of disease
and at least one repeat disease assessment.
History, physical examination (symptom directed), WHO
performance status and weight were performed pre-dose on days
-14, -7, 1, 8, 15 and 22 of cycles 1 and 2, then day 1 of each cycle
thereafter. AEs were graded according to NCI CTCAE Version
4.02. CA19-9 was measured before treatment on day -14 and then
on day 1 of each cycle. Radiological assessments (CT, MRI, X-ray)
were repeated every 8 weeks and tumour response was assessed
based on the Response Evaluation Criteria in Solid Tumors
(RECIST) v1.1 (Eisenhauer et al, 2009). Time to progressive disease
(as per RECIST v1.1) and survival at 6 months and 1 year were
calculated from cycle 1, day -14 when MK-0752 was administered
for the first time.
Dose modifications and duration of treatment. Dose and dose
level refer to both MK-0752 and gemcitabine unless otherwise
stated. Grade 1 AEs required no dose modification. At first
occurrence of a grade 2–4 non-haematological or gastrointestinal-
related AEs, the dose of both MK-0752 and gemcitabine were
withheld until the AE grade returned to a grade 1. With grade 2
haematological AEs, treatment could be continued at the same
dose level unless the platelet count was o75 109 l-1. If initially a
grade 3 or 4 AE, the dose was then reduced by one dose level (for
both MK-0752 and gemcitabine) or discontinued at the discretion
of the investigator. The gemcitabine dose level was not reduced
below 600mgm-2. If a patient experienced several AEs, then the
recommended dose adjustment to reduce the dose to the lowest
level was used and the schedule maintained. MK-0752 was reduced
first unless either stated otherwise or the AE was considered related
(almost certainly, probably or possibly) to gemcitabine only. If the
starting dose was not tolerated then the patient could continue to
receive gemcitabine as a single agent. Patients requiring a delay of
42 weeks were removed from study.
Combination treatment continued for six cycles unless the
patient was withdrawn, there was evidence of disease progression
or the patient was experiencing unacceptable toxicity. If a patient
was benefiting from treatment (i.e., has stable or responding
disease as measured by RECIST 1.1) and the benefit – risk balance
was considered acceptable then further treatment could be given
following approval from the Sponsor for up to six additional cycles.
Patients were followed up for 28 days after the last administration
of MK-0752 or gemcitabine. All patients were followed up for
disease progression and survival every two months, continued for
12 months following cycle 1, day 1. Beyond 12 months, patients
were followed up for progression free and overall survival data
collection (during their standard clinic visits) and the period for
collecting this data continued for 12 months from cycle 1 day 1 of
the final patient recruited to the study.
PK analysis. Plasma samples for analysis of MK-0752 levels were
collected at the following time points in cycle 1: day  14:
immediately prior to MK-0752 dose; day -7: immediately prior
to MK-0752 dose and then at 1, 4, 8 and 24 h post-dose; post day
 7: approximately at the same time as the second tumour biopsy
sample (within 24–48 h of day -7); day 1: immediately prior to
MK-0752 dose and then at 1, 4, 8 and 24 h post-dose. Samples were
collected within 10% of the proposed time following MK-0752
dosing. Tumour biopsy was collected at baseline and within 72 h
post day -7 dose of MK-0752. Tumour and plasma concentrations
of MK-0752 were evaluated by Merck, Kenilworth, NJ, USA. MK-
0752 was isolated from blood or tumour by protein precipitation
and analysed by liquid chromatography/tandem mass spectro-
metry (LC–MS/MS). Non-compartmental PK analysis was per-
formed using Phoenix v6.0 software on non-rounded bioanalytical
data. The PK parameters determined for MK-0752, alone and in
combination with gemcitabine, include the maximum observed
plasma concentration (Cmax), time to reach Cmax (Tmax), and
the area under the plasma concentration time curve (AUC). The
same calculations were used to measure plasma and tissue
concentrations.
PD analysis. Tumour biopsy samples were used to undertake
transcriptional profiling to assess Notch pathway activity, and
immunohistochemical (IHC) analysis of certain Notch target
genes. The timing of tissue collection is described in the PK
methods section. The tumour tissue, where accessible by endo-
scopic ultrasound (EUS) or CT-guided biopsy, was obtained by the
same technique on each occasion with three to five passes made at
each attempt. The following samples were collected from each
patient; (a) specimen for formalin fixed paraffin embedded (FFPE)
slides; (b) specimen for RNA analysis stored in RNAeasy (Qiagen,
Manchester, UK); c. specimen for PK analysis (methods described
in the PK section). These were collected following standard
internal hospital procedures. The FFPE samples for IHC were
processed and analysed at the CRUK Cambridge Institute
following internal laboratory procedures. Notch pathway inhibi-
tion was evaluated in tumour tissue by assessing IHC for certain
target genes (Hes and Hey family). The Hes1 antibody (clone
NM1; MBLI; 1:250 dilution), and Hey1 antibody (ab22614; Abcam;
1:50 dilution) were used. To ensure uniformity of staining, all slides
were stained in a single batch. Scoring of the immunohistochem-
istry was carried out blinded. A grade of 0-3 was given to each
sample depending on the frequency and intensity of staining; 0: no
staining; 1: low frequency and/or intensity of staining; 2: frequent
and moderate intensity or moderate frequency and high intensity;
3: very frequent and high intensity. In the case of Hes1, nuclear
staining in tumour cells was scored. Nuclear and cytoplasmic Hey1
was assessed in tumour and stromal cells. IHC assay scoring was
analysed using the statistical software package GraphPad Prism
(San Diego, CA, USA) version five.
All other PD tumour samples and hair follicles were shipped
directly from the CRUK Cambridge Institute to LabCorp (formerly
Covance Genomics Lab) Seattle, WA, USA for RNA extraction and
Affy microarray processing. Plucked hair follicles were obtained
from patients participating at baseline and 6–8 h after the MK-0752
administration on day -7, always taken from the patients head. The
published refined signature in hair follicles exhibited a strong linear
correlation with plasma MK-0752, confirming its utility as a
surrogate PD biomarker. (Krop et al, 2012). Hair follicles are
extracted using the Promega SV total RNA isolation kit. The tumour
samples were extracted using homogenisation in RLT buffer, Trizol
extraction and final isolation using the Promega SV96 isolation kit.
All RNA samples were treated with DNAse as part of the process.
Fifty ng of total RNA was amplified using the NuGEN Ovation
Whole Blood Solution protocol (NuGEN, San Carlos, CA, USA) as
described by the manufacturer. Amplified biotin-labelled material
was hybridised to custom designed Affymetrix microarrays, one
sample per array. Hybridisation, washing and scanning were
MK-0752 and gemcitabine in pancreatic adenocarcinoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.495 795
completed as recommended by the manufacturer LabCorp Clinical
Trials in Seattle.
RESULTS
Patient characteristics. A total of 44 eligible patients were enroled
in this study between 26-May-2010 and 10-Oct-2014, of whom 42
received treatment and were therefore evaluable for safety analysis.
Baseline characteristics are described in Table 1. The majority of
patients had stage IV pancreatic adenocarcinoma (93%) and 30%
had received prior chemotherapy.
Dose escalation and MTD. During dose escalation, where safety
constraints permitted, patients were commenced on study in pairs
as per the Bayesian algorithm, described previously (Whitehead
et al, 2012) (Supplementary Figures 1 and 2). At each stage of dose
escalation, the Bayesian algorithm recommended MK-0752 doses
for use with 800 and 1000mgm-2 of gemcitabine, which were
thought most likely to be associated with a DLT risk of 0.2 on the
basis of data available from patients evaluable for determination of
the MTD. None of the patients in dose levels 1–3, a and b arms or
dose level 4b, experienced a dose-limiting toxicity (DLT). The
RP2D of both single agents was shown to be safe in combination
(MK-0752 1800mg p.o. once weekly and gemcitabine 1000mgm-2
(i.v. days 1, 8 and 15 or a 28 day cycle). The Bayesian algorithm
would permit further dose escalation, but accruing PK data (see
below) confirmed previous findings that dose escalation beyond
the RP2D of MK-0752 did not lead to higher plasma AUCs (Krop
et al, 2012). Two dose-limiting toxicities were observed: grade 3
hypokalaemia was observed at MK-0752 2400mg/gemcitabine
800mgm-2 (dose level 5b) in one patient and grade 3 fatigue was
observed in 1 patients at MK-0752 1800mg/gemcitabine 1000mg
m-2 (dose level 4a) (Supplementary Figure 2). Of the 42 patients
who received treatment, 31 patients (74%) had at least one dose
delay and/or dose modification (mostly reductions and delays and
missed doses). Three patients (7%) required at least one dose
reduction of MK-0752 and 4 patients, at least one dose reduction
of gemcitabine (9%). One patient required dose reduction of both
drugs. Dose escalation continued to dose level 5b (MK-0752
2400mg/gemcitabine 800mgm-2). Dose level 6 was not explored.
The MTD of both drugs combined was recommended to be the
same as the RP2D of both drugs as single agents (MK-0752
1800mg and gemcitabine 1000mgm-2) on the basis of clinical and
safety profiles. At the point the study closed, according to the
Bayesian procedure the dose combination with the highest
probability of having a toxicity risk of 0.2 was the RP2D of both
drugs as single agents.
Safety and tolerability. The incidences of grade 3 and 4 AEs
deemed to be related to either study drug are listed by dose level
(Table 2). Gastrointestinal-related AEs were common although
primarily grade 1 or 2 (nausea 23 pts (55%); vomiting 23 pts (55%);
diarrhoea 20 pts (48%)). Other AEs affecting over 20% of patients
included; thrombocytopenia (40.5%), anaemia (41%), anorexia
(33%), fatigue (31%), neutropenia (29%) and transaminitis. Seven
patients died during the active treatment period of the study, that
is, within 28 days of their last IMP administration. Three deaths
were related solely to progressive disease and 1 patient died due to
progressive disease associated with an intracranial haemorrhage
and disseminated intravascular coagulation (DIC). The remaining
3 patients died due to a thromboembolic event leading to cardiac
arrest, sepsis and aspiration pneumonia. These deaths were not
considered related to study treatment.
Pharmacokinetics. Data from 40 patients were available for
plasma PK analysis. Plasma MK-0752 exposure (AUCo-t) and
Cmax did not appear to be affected by the addition of gemcitabine,
as parameters at day 1 (MK-0752þ gemcitabine) are comparable
with parameters at day -7 (MK-0752 alone) (Figure 1A and B).
Comparing MK-0752 exposure across the dose groups, there was
no increment in exposure beyond the RP2D single-agent dose
(1800mg weekly). Summary data for the RP2D of MK-0752
(1800mg) are shown in Figure 1C.
Eighteen paired patient biopsies were available for baseline and
day -7, tumour PK analysis. MK-0752 was detected in day -7
tumour samples, with concentrations ranging from 480 to
30 600 ng g-1 (Figure 1D). The data are limited, but there appeared
to be no increment in the tumour MK-0752 concentration between
the 1500 and 2100mg doses.
Pharmacodynamics. The ‘Notch signature score’ was analysed in
hair follicles from 37 patients. Significant inhibition of Notch
signalling post MK-0752 treatment, as evidenced by negative
signature scores, was observed in 25/29 pts (Figure 2). There was
no relationship between MK-0752 dose and the fold-change in
Notch score, although number of samples was limited.
Forty-six pre- and post-treatment samples from 25 patients
were received for IHC analysis. The biopsy samples were a mixture
of Endoscopic Ultrasound-guided Fine Needle Aspirate (EUS
FNA) from primary tumours and image-guided core biopsies from
metastatic deposits. These biopsy samples were too small to be able
to examine the endothelium, only the tumour cells were analysed.
The 46 samples were comprised of 20 pairs of matched pre- and
post-treatment biopsies. Five patients only had pre-treatment
biopsies, and did not contribute to the comparison. Nine pairs
could not be evaluated due to insufficient tissue. Hes1 and Hey1
target genes were not highly expressed in all baseline tumour
biopsy samples, as had been expected. Of the 20 evaluated blocks
for Hes1 staining, 4 were scored as Grade 0, indicating a lack of
nuclear Hes1 staining. Seven samples were scored as Grade 1 and 8
as Grade 2. Only 1 of the evaluable blocks was scored as Grade 3
(Supplementary Figure 1).
CA19-9 levels and percentage changes were measured during
the study, however patient numbers were small and it is not
possible to draw any conclusions based on the limited number of
results obtained.
Table 1. Baseline patient characteristics
Characteristics Male Female All patients
Gender 26 18 44
Age (years)
Median 65.5 62 64
Range 40–77 39–74 39–77
ECOG performance status
0 11 5 16
1 15 13 28
Disease stage
3 2 1 3
4 24 17 41
Prior systemic anticancer therapy
Yesa 9 4 13
No 17 14 31
Prior Whipple’s surgery
Yes 3 1 4
No 23 17 40
Prior radiotherapy
Yes 0 0 0
No 26 18 44
Abbreviation: ECOG=Eastern Cooperative Oncology Group.
aPrior systemic anticancer therapy included gemcitabine-based regimes in 9 out of 13
patients (including in the adjuvant setting), irinotecan-based regimes in 3 out of 13 patients.
and 1 patient had received FOLFIRINOX.
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Efficacy. In this study, 26 out of 44 evaluable patients were
assessed for efficacy, as they received at least 1 complete cycle
of treatment with MK-0752 alone followed by MK-0752 in
combination with gemcitabine. The commonest reason for
becoming non-evaluable during cycle 1 was symptomatic dete-
rioration unrelated to study medication. Of the 26 patients
evaluable patients, 19 received at least 2 cycles of treatment,
provided baseline evaluations of disease and at least 2 repeat sets of
disease assessments (patients were required to have at least one
scan following their baseline scan to be evaluable, plus a second
scan to confirm the findings of the first where there was a response
(CR or PR)), so only these patients were evaluable for tumour
response (RECIST 1.1). The median time to progressive disease
was 169 days. Thirteen patients achieved stable disease, but only
one patient achieved a confirmed partial response. This patient
completed eight cycles of treatment. Nine patients were treated at
the RP2D, and were evaluable for determination of the MTD. Of
those, only 3 patients survived46 months and 2 of these patients
survived X1 year. All patients in the RP2D population had stage
IV pancreatic cancer at baseline. In terms of overall efficacy, the
median overall survival time was 246 days in the response
population (n¼ 19), including patients who had been treated at all
dose levels.
DISCUSSION
The Notch signalling pathway is known to be an important target
in pancreatic adenocarcinoma (PDAC), with components of the
pathway found to be upregulated in various different cell types
(Miyamoto et al, 2003; Mullendore et al, 2009; Cook et al, 2012).
There are multiple published pre-clinical studies in PDAC, using
various Notch pathway inhibitors alone and in combination, with
encouraging results (Plentz et al, 2009; Yao and Qian, 2010; Cook
et al, 2012; Yabuuchi et al, 2013; Palagani et al, 2014, ). The most
common therapeutic used in these studies have been GSIs. With
these supportive pre-clinical findings, a phase I trial of MK-0752 in
combination with gemcitabine in PDAC patients was undertaken.
At the time of opening, it was the first trial to examine a GSI in
patients with PDAC.
We observed that gemcitabine and MK-0752, can be combined
at full, single-agent RP2Ds (MK-0752 1800mg p.o. weekly and
gemcitabine 1000mgm-2 i.v. days 1, 8 and 15 of a 28 day cycle) and
the regimen is well tolerated. The adaptive Bayesian algorithm used
in the trial would have allowed further dose escalation beyond the
single-agent RP2Ds, however the PK analysis revealed a plateau in
plasma MK-0752 at the 1800mg dose. As no severe adverse events
were experienced the trial could have been more adaptive in its
design by dropping the 800mg gemcitabine cohort to potentially
allow more rapid dose escalation using all the available data from
all patients in each dose decision. The regimen was well tolerated
although grade 1 and 2 gastrointestinal-related adverse events were
common. No unexpected adverse events were identified. The
occurrence of gastrointestinal, haematological and biochemical
changes in liver function tests (transaminitis) are all recognised
adverse events associated with MK-0752 and gemcitabine, when
administered as single agents. Fatigue and thrombocytopenia were
also commonly seen.
Of the 19 patients that had response assessments, 1 patient had
a confirmed partial response and 13 patients stable disease. Three
of 9 patients in the RP2D population survived for longer than 6
months, and 2 out of 9 remained alive at 1 year. This outcome may
have been predicted following gemcitabine alone. The PK analysis
revealed a plateau in plasma PK at the 1800mg MK-0752 level.
Table 2. Drug-related AEs Xgrade 3a
Related adverse event
(preferred term) (no. of
events)
MK1200þ
GEM800
(n¼ 6)
Dose level 1
MK1200þ
GEM1000
(n¼ 3)
Dose level
2a
MK1500þ
GEM800
(n¼3)
Dose level
2b
MK1500þ
GEM1000
(n¼4)
Dose level
3a
MK1800þ
GEM800
(n¼ 3)
Dose level
3b
MK1800þ
GEM1000
(n¼ 7)
Dose level
4a
MK2100þ
GEM800
(n¼3)
Dose level
4b
MK2400
(n¼1)
Dose level 5b
Any XG3 AE 8 6 2 2 11 11 10 1
Anaemia 2 1 1 1 1 2 2
Lymphocytes decreased 1 1
Neutropenia 1 4 1
Thrombocytopenia 1
WBC decreased 1
Diarrhoea 1
Dysphagia 1
Nausea 1 1
Vomiting 2
Fatigue 1 1
ALT increased 3 1
AST increased 1 1
Alk Phos increased 1
Bilirubin increased 2 1
Hypokalaemia 1 2 1
Hypophosphatemia 3 1 1 1
DIC 1
Intracranial haemorrhage 1
Debility 1
Abbreviations: AE=adverse events; Alk Phos=Alkaline Phosphatase; ALT¼ alanine amino-transferase; AST=aspartate amino-transferase; DIC=disseminated intravascular coagulation;
WBC=white blood cells.
aOnly patients that experienced a Xgrade 3 adverse event are recorded in this table (n¼ 30 out of 44 patients).
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These results are similar to those previously reported in a study
utilising MK-0752 as a single agent (Krop et al, 2012). The PK
profile of MK-0752 was unaffected by gemcitabine. Importantly it
was feasible to measure the concentration of
MK-0752 in a limited number of tissue samples, proving that this
drug does enter tumour tissue.
Multiple PD endpoints were examined both as surrogates for
tumour activity (hair follicle gene expression array) and in the
tumour (Hes1 and Hey1 target genes IHC and gene expression
array). Paired biopsies were undertaken in over 50% of the patients
on study, but the quality of these biopsies was variable. Pancreatic
biopsies are notoriously difficult to obtain, and even in metastatic
samples we did not always obtain the amount of tumour tissue
required for informative PD assay investigations. In the samples
with adequate amounts of tissue for analysis the expression of the
Notch target genes we analysed was inconsistent with pre-clinical
results (Cook et al, 2012). Several screening samples were graded
0–1, which confounds the assessment of the impact of therapy.
Although two of the samples at the higher doses appeared to have
less nuclear Hes1 staining post-treatment, the small numbers make
it impossible to draw any conclusions as they were not consistently
downregulated post-treatment.
Significant inhibition of Notch signalling post MK-0752
treatment was observed using the gene expression array from hair
follicles. In summary, Notch pathway modulation was not
identified in the tumour samples that were analysed, in spite of
there being evidence of relevant exposure to MK-0752 being
present in the samples. However, the unexpectedly low level
expression of Hes1 and Hey1 is likely to have confounded these
analyses.
GSIs have been the most broadly developed Notch pathway
inhibitor (De Kloe and De Strooper, 2014). However, due to their
lack of specificity, gastrointestinal side effects, and disappointing
response rates further development may be challenging.
RO4929097 is a GSI that has been used in single agent and
combination early phase studies, including one in combination
with gemcitabine in solid tumours, and one as GSI monotherapy in
PDAC. (De Jesus-Acosta et al, 2014; Richter et al, 2014). Many
trials involving this agent have been published, however due to lack
of clinical activity in the phase II setting development of the
compound has been discontinued (Strosberg et al, 2012; Tolcher
et al, 2012; Diaz-Padilla et al, 2013, 2015; Lee et al, 2015). There are
multiple other GSIs in clinical development both alone and in
combination in various different tumour types (Gavai et al, 2015;
Messersmith et al, 2015; Pant et al, 2016). None are yet to make it
to development in the phase III setting in cancer.
GSIs are known to catalyse the proteolysis of many other
substrates, therefore it is possible anti-tumour effects from GSIs
could be attributed to one of these rather than solely inhibition of
Notch signalling (Groth et al, 2010). Therefore, although the Notch
pathway remains an interesting and relevant target in pancreatic
cancer, newer active targeted agents directed against the pathway
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Figure 1. Plasma and tumour MK-0752 PK analysis. (A) Plot of area under the curve (AUC0-t) vsMK-0752 dose (plasma). (B) Plot of Cmax (ngml
-1) vs
MK-0752 dose (plasma). (C) Statistical summary of PK parameters at RP2D of MK-0752 (1800mg). (D) MK-0752 levels in tumour tissue (ngg-1
tissue) plotted against dose of MK-0752. AUC0-t¼ area under the time:plasma concentration curve from time 0 to last measurable time point;
Cmax¼maximum concentration; CV¼ coefficient of variation as a percentage; ng¼ nanograms; PK=pharmcokinetics; RE¼ relative error;
SD¼ standard deviation; Tmax¼ time of maximum concentration.
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are needed. Given the expression of multiple different ligands and
receptors from the Notch pathway in pancreatic cancer, and the
role it has in the tumour cells and the microenvironment, it would
be challenging to decide exactly which components of the pathway
to target if not using a pan-Notch inhibitor. Also given the fact that
not all Notch components are equivalent (Notch1 vs Notch3
receptors and Jagged 1 vs Dll4 ligands) it is also possible that
specifically targeting individual or subsets of components is needed
to elicit the desired effect.
Although we were able to administer MK-0752 and gemcitabine
in combination, at their single agents RP2Ds, the activity seen,
albeit in a small number of patients, was similar to that which
would have been anticipated with gemcitabine alone. As this study
commenced in 2010, alternative first line treatments for metastatic
PDAC have been identified. These include FOLFIRINOX and nab-
paclitaxel with gemcitabine (Conroy et al, 2011; Von Hoff et al,
2013). Therefore, we did not feel that the gemcitabine and MK-
0752 combination explored in our study, merits further evaluation.
However, Notch pathway inhibitors and chemotherapy combina-
tions are being evaluated and data from our trial and the literature
would suggest that the chemotherapy dosages will not need to be
attenuated, with the addition of a Notch pathway inhibitor (Richter
et al, 2014).
In summary, gemcitabine and MK-0752, can be combined at
full, single-agent RP2Ds and the regimen was well tolerated. Some
clinical activity was seen although the data were similar to what
would have been expected with single-agent gemcitabine. Our data
suggest that chemotherapy doses may not need to be attenuated in
combinations including Notch pathway inhibitors.
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